Various types of non-routine dose fractionation were used in 2062 patients with malignant tumors of different sites. The conclusion was that superfractionation was more preferable for tumors with a high proliferative pool, with fast growth rates, marked radiosensitivity. It ensures the protection of normal tissues without a decrease or even with an increase in an antitumor effect. Such fractionation can be recommended when large tissue areas are to be irradiated. Dynamic dose fractionation regimens proved to be more effective than the use of large fractions not only in squamous cell carcinoma but also in sarcoma both before operation and as therapy after a radical program.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Alpha/beta values in pediatric medulloblastoma: implications for tailored approaches in radiation oncology.
Radiat Oncol
January 2025
Department of Radiotherapy and Radiooncology, Medical Faculty, Heinrich Heine University, Moorenstr. 5, 40225, Dusseldorf, Germany.
Background: Medulloblastoma is the most common malignant pediatric brain tumor, typically treated with normofractionated craniospinal irradiation (CSI) with an additional boost over about 6 weeks in children older than 3 years. This study investigates the sensitivity of pediatric medulloblastoma cell lines to different radiation fractionation schedules. While extensively studied in adult tumors, these ratios remain unknown in pediatric cases due to the rarity of the disease.
View Article and Find Full Text PDFEnhancing immunotherapy efficacy with synergistic low-dose radiation in metastatic melanoma: current insights and prospects.
J Exp Clin Cancer Res
January 2025
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Recent advances in oncology research have highlighted the promising synergy between low-dose radiation therapy (LDRT) and immunotherapies, with growing evidence highlighting the unique benefits of the combination. LDRT has emerged as a potent tool for stimulating the immune system, triggering systemic antitumor effects by remodeling the tumor microenvironment. Notably, LDRT demonstrates remarkable efficacy even in challenging metastatic sites such as the liver (uveal) and brain (cutaneous), particularly in advanced melanoma stages.
View Article and Find Full Text PDFStereotactic body radiotherapy for non-spine bone metastases: A meta-analysis and international stereotactic radiosurgery society (ISRS) clinical practice guidelines.
Radiother Oncol
January 2025
The Royal Marsden NHS Foundation Trust, Sutton, UK; The Institute of Cancer Research, Sutton, UK.
Background: While SBRT to NSBM has become common, particularly in the oligometastatic population, the approach to treating non-spine bone metastases (NSBM) with stereotactic body radiotherapy (SBRT) varies widely across institutions and clinical trial protocols. We present a comprehensive systematic review of the literatures to inform practice recommendations on behalf of the International Stereotactic Radiosurgery Society (ISRS).
Methods: A systematic literature review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
Radiobiologically equivalent deformable dose mapping for re-irradiation Planning: Implementation, Robustness, and dosimetric benefits.
Radiother Oncol
January 2025
Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, United States. Electronic address:
Background: Re-irradiation in radiotherapy presents complexities that require dedicated tools to generate optimal re-treatment plans. This study presents a robust workflow that considers fractionation size, anatomical variations between treatments, and cumulative bias doses to improve the re-irradiation planning process.
Methods: The workflow was automated in MIM® Software and the Elekta© Monaco® treatment planning system.
The 2024 Assisi think tank on breast cancer: Focus on the use of a tumour bed boost after breast conserving therapy.
Breast
January 2025
Department of Radiation Oncology, Iridium Netwerk, Wilrijk, Antwerp, Belgium; University of Antwerp, Faculty of Medicine and Health Sciences, Wilrijk, Antwerp, Belgium. Electronic address:
At the Fifth Assisi Think Tank Meeting (ATTM) on breast cancer, one key topic was the role of tumor bed boost in invasive breast cancer and ductal carcinoma in situ. The need for a tumor bed boost after whole breast irradiation is controversial. A literature review assessed boost indications, target volume definition, techniques, dose fractionation, and ongoing trials.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!